NCT07409454RecruitingPhase 2
A Prospective, Single-Arm Clinical Trial of MRD-Guided BCMA/CD3 Bispecific Antibody as Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China1 site in 1 country20 target enrollmentStarted: July 7, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Minimal residual disease (MRD) negativity conversion rate
Study Overview
Brief Summary
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Be able to understand and voluntarily signs the informed consent form (ICF).
- •Age ≥ 18 years.
- •Newly diagnosed multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.
- •MRD positivity (≥10-⁵) detected by EuroFlow.
- •Previous therapy limited to first-line treatment only, including: (1) Induction therapy with a 3- or 4-drug regimen containing a proteasome inhibitor and/or an immunomodulatory drug and/or an anti-CD38 monoclonal antibody; (2) Single or tandem autologous stem cell transplantation (ASCT); (3) Up to 2-4 cycles of consolidation therapy post-ASCT are permitted, with the total number of induction plus consolidation cycles not exceeding
- •Completion of ASCT within ≤12 months from the start of induction therapy; and ≤6 months from the most recent ASCT at enrollment (≤7 months if consolidation therapy was administered).
- •No prior maintenance therapy.
- •Achieved at least a partial response (≥PR) according to the IMWG 2016 response criteria.
- •Presence of measurable disease at diagnosis.
Exclusion Criteria
- •Prior treatment with genetically modified adoptive cellular therapy.
- •History of allogeneic stem cell transplantation or solid organ transplantation.
- •Disease progression prior to enrollment (per IMWG 2016 response criteria), or presence of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome, or light-chain amyloidosis not attributable to symptomatic multiple myeloma.
- •Central nervous system involvement.
Arms & Interventions
BsAbs-treatment group
Experimental
Intervention: anti-BCMA/CD3 bispecific antibody (Drug)
Outcomes
Primary Outcomes
Minimal residual disease (MRD) negativity conversion rate
Time Frame: Up to 24 months
Secondary Outcomes
- Duration of MRD negativity(Up to 24 months)
- Progression-Free Survival(From enrollment to the date of disease progression or death, up to approximately 24 months.)
- Overall Survival (OS)(From start of treatment until death from any caus, up to approximately 24 months.)
- Incidence and severity of adverse events (AEs)(From the first dose through 30 days after the last dose, up to approximately 24 months.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNSCLC (Non-small Cell Lung Carcinoma)Stage IIIEGFR Uncommon MutationsNCT07314216Hunan Cancer Hospital15
Recruiting
Not Applicable
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell MalignanciesRelapsed/Refractory B-cell MalignanciesNCT07345728Donghua Zhang28
Recruiting
Phase 1
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological MalignanciesAMLLeukemiaAML (Acute Myelogenous Leukemia)MDS (Myelodysplastic Syndrome)MDSNCT07347171Cullgen (Shanghai),Inc45
Not yet recruiting
Phase 4
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic CancerPancreatic Cancer Non-resectableNCT07302841Tianjin Medical University Cancer Institute and Hospital28
Not yet recruiting
Phase 3
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsAdvanced CholangiocarcinomaIntrahepatic Cholangiocarcinoma (Icc)NCT07328919TransThera Sciences (Nanjing), Inc.138